Enterprise Value

1.148B

Cash

528.1M

Avg Qtr Burn

-43.67M

Short % of Float

23.33%

Insider Ownership

6.52%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Nirogacestat (gamma secretase inhibitor) Details
Desmoid tumors

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Mirdametinib Details
NF1-associated Plexiform Neurofibromas

Phase 2b

Update

Nirogacestat Details
Cancer, Ovarian cancer, recurrent ovarian granulosa cell tumors

Phase 2

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1b

Data readout

Phase 1

Update